While Myriad Genetics, Inc has underperformed by -0.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -55.13%, with highs and lows ranging from $29.30 to $9.36, whereas the simple moving average fell by -49.96% in the last 200 days.
On March 12, 2025, Piper Sandler Upgraded Myriad Genetics, Inc (NASDAQ: MYGN) to Overweight. A report published by Craig Hallum on February 12, 2025, Initiated its previous ‘Buy’ rating for MYGN. UBS also rated MYGN shares as ‘Neutral’, setting a target price of $18 on the company’s shares in an initiating report dated December 10, 2024. Leerink Partners December 09, 2024d the rating to Market Perform on December 09, 2024, and set its price target from $30 to $21. Morgan Stanley initiated its ‘Equal-Weight’ rating for MYGN, as published in its report on September 19, 2024. Wells Fargo’s report from August 28, 2024 suggests a price prediction of $35 for MYGN shares, giving the stock a ‘Overweight’ rating. Scotiabank also rated the stock as ‘Sector Outperform’.
Analysis of Myriad Genetics, Inc (MYGN)
Further, the quarter-over-quarter increase in sales is 7.12%, showing a positive trend in the upcoming months.
Myriad Genetics, Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -17.15% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.65, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and MYGN has an average volume of 1.09M. On a monthly basis, the volatility of the stock is set at 6.68%, whereas on a weekly basis, it is put at 3.68%, with a loss of -1.38% over the past seven days. Furthermore, long-term investors anticipate a median target price of $17.09, showing growth from the present price of $9.98, which can serve as yet another indication of whether MYGN is worth investing in or should be passed over.
How Do You Analyze Myriad Genetics, Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.54%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 101.81% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
